The shares are listed on Nasdaq

Davis Polk advised the representatives of the underwriters on a $75 million SEC-registered offering of 30,000,000 shares of common stock of Esperion Therapeutics, Inc. The underwriters have a 30-day option to purchase up to an additional 4,500,000 shares of common stock from Esperion. The common stock is listed on the Nasdaq Global Market under the symbol “ESPR.”

Esperion, based in Ann Arbor, Michigan, is a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C).

The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Michael Stromquist and associate Cheridan Christnacht. The intellectual property team included partner David R. Bauer and associates Anthony Tran and Anne Kim. Counsel Yixuan Long and associate Hunter P. Shaw provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post